Key result
GLP-1 RAs linked to ~24% lower dementia risk vs DPP4is but higher risk vs SGLT2is.
Why the study?
Type 2 diabetes is associated with increased dementia risk, but comparative data across newer glucose-lowering therapies remain limited.
Does initiation of GLP-1 receptor agonists reduce incident dementia in older adults with type 2 diabetes compared to DPP4 inhibitors or SGLT2 inhibitors?
Population
Adults aged ≥50 with T2D and no prior dementia
Comparison
GLP-1 RA initiation vs DPP4i or SGLT2i initiation
Design
Retrospective cohort study emulating a target trial
Follow-up
Median 3.0 years (vs DPP4i) and 2.4 years (vs SGLT2i)
Authors
Loading...
GLP-1 RA initiation was associated with differential dementia risk versus DPP4i and SGLT2i in older T2D adults; leaves open causality and optimal agent selection.
Does initiation of GLP-1 receptor agonists reduce incident dementia in older adults with type 2 diabetes compared to DPP4 inhibitors or SGLT2 inhibitors?
In older adults with type 2 diabetes, GLP-1 receptor agonists are associated with a lower risk of incident dementia compared to DPP4 inhibitors, but a higher risk compared to SGLT2 inhibitors.
Zhou et al. (2025) studied this question. GLP-1 receptor agonists were associated with a 24% lower dementia risk than DPP4 inhibitors (HR 0.76) but a 53% higher risk than SGLT2 inhibitors (HR 1.53) in older adults with T2D.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: